Worldwide access to treatment for end-stage kidney disease: a systematic reviewThaminda Liyanage, Vlado Perkovic, Amit X. Garg et al.|The Lancet|2015Cited by 2.3k
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Hans‐Henrik Parving et al.|The Lancet|2019Cited by 609
PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX AloneJ. Wang, Jean‐Yves Douillard, Zhongyun Zhao et al.|Value in Health|2012Cited by 0
Quality-Adjusted Survival in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox AloneJ. Wang, Jean‐Yves Douillard, Zhongyun Zhao et al.|Annals of Oncology|2012Cited by 0